Phase 3 Study of Stem Cell Transplantation in Multiple Myeloma Patients Showing Early Benefits
Results from an ongoing clinical trial supports the use of upfront autologous stem cell transplantation (ASCT) to treat multiple myeloma patients age 65 or younger.